DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR CANDESARTAN CILEXETIL
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
All Clinical Trials for Candesartan Cilexetil
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00108706 | Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | Unknown status | Takeda | Phase 4 | 2004-12-01 | The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke. |
| NCT00108706 | Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) | Unknown status | City Hospitals Sunderland NHS Foundation Trust | Phase 4 | 2004-12-01 | The aim of this study is to determine whether it is safe and effective to give the Angiotensin Receptor Blocker (ARB) Candesartan within the first 72 hours following acute stroke. |
| NCT00125463 | Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients | Unknown status | The Japanese Society of Hypertension | Phase 3 | 2001-09-01 | The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil– Blopress®) and a calcium channel blocker (amlodipine besilate– Norvasc®/Amlodin®) in terms of the incidence of cardiovascular events among high-risk hypertensive patients. |
| NCT00139386 | Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial | Completed | Japan Heart Foundation | Phase 4 | 2005-10-01 | Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation. |
| NCT00139386 | Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial | Completed | The 4C trial bureau | Phase 4 | 2005-10-01 | Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation. |
| NCT00139386 | Candesartan for Prevention of Cardiovascular Events After Cypher or Taxus Coronary Stenting (4C) Trial | Completed | Kumamoto University | Phase 4 | 2005-10-01 | Candesartan is effective in preventing cardiovascular events in patients without restenosis after coronary angioplasty. Therefore, the investigators hypothesized that candesartan after drug-eluting stent (DES) implantation was also effective in preventing cardiovascular events. The purpose of this study is to investigate whether an angiotensin II receptor blocker, candesartan, is effective in reducing the incidence of cardiovascular events after drug-eluting stent implantation. |
| NCT00150631 | Danish Hypertension Prevention Project - DHYPP | Unknown status | AstraZeneca | Phase 3 | 2000-11-01 | The present study examine healthy, normotensive subjects 18 to 36 years of age whose both parents have essential hypertension. The subjects receive treatment with either the AT1-antagonist candesartan cilexetil, 16 mg daily or placebo for one year. Then, treatment is withdrawn and the subjects is followed for 10 years to determine if the treatment has been able to either prevent or delay the development of hypertension. The primary objective is to determine whether pharmacological treatment with an angiotensin receptor blocker is able to restrain or delay the progression to hypertension. Secondary objectives are to investigate whether any long-term effect on blood pressure is related to the effect of treatment on renal haemodynamic function, or on the left ventricle mass. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Candesartan Cilexetil
Condition Name
Condition MeSH
Clinical Trial Locations for Candesartan Cilexetil
Trials by Country
Clinical Trial Progress for Candesartan Cilexetil
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Candesartan Cilexetil
Sponsor Name
